The aim of this trial was to evaluate the effect of in-feed doxycycline (DOXY) on the control of ileitis in weaned piglets. On a farm with a previous history of ileitis outbreaks, 288 piglets at the age of weaning (25 +/- 2 days old) were divided into four experimental groups, each group comprising three pens with 24 piglets in each pen. Non-medicated animals served as negative control (NC) group, whereas groups DOXY-50, DOXY-125 and DOXY-250 received doxycycline via feed at 50, 125 and 250 ppm, respectively. Therapy lasted for 14 days followed by an observation period of 28 days. In conclusion, administration of doxycycline at a dose rate of 125 or 250 ppm had beneficial effect compared with the NC group. in terms of the reduction of diarrhoea prevalence, the enhancement of growth performance and the reduction of prevalence of Lawsonia intracellularis in the intestine, as shown either by the PCR method or by specific histopathological examinations. Treatment with 250 ppm of doxycycline for a fortnight interval post-weaning seems to be beneficial leading to better growth rates of piglets not only during treatment period, but also throughout the whole nursery phase.

Antidepressants are a commonly used, easily accessible, and overall safe treatment option for post-traumatic stress disorder (PTSD). The present review aims to evaluate the efficacy and safety of antidepressants in treating sleep disturbances in patients with PTSD. PubMed and the Cochrane Li- brary were searched (July 2022) for systematic reviews and meta-analyses on the treatment of PTSD. Moreover, PubMed and ClinicalTrials.gov were searched for individual trials investigating the antidepressant treatment of PTSD (up to September 2022), and reference lists of all relevant identi- fied studies were screened. Sleep-related outcomes, i.e., total sleep time, sleep quality, dreams/ nightmares, insomnia, and somnolence, were extracted independently by at least two reviewers. Meta- analytic evaluations were performed wherever possible. 39 randomised controlled trials (RCTs) were identified; data from pooled analyses, reviews, and observational studies were used for antidepressants with a weak evidence base or when their findings were deemed important. Overall, scarce data exist on the effects of antidepressants on sleep outcomes among patients with PTSD. Some evidence may support the use of amitriptyline, nefazodone, paroxetine, and sertraline for improving sleep in patients with PTSD. Τhere was a meta-analytical trend indicating improvement of nightmares with fluoxetine, less insomnia with amitriptyline and more with brofaromine, as well as more somnolence with paroxe- tine vs. placebo, respectively. However, data from more than 1 RCT with a considerable number of pa- tients were only available for paroxetine. Evidence is insufficient to draw safe conclusions. More and better-designed RCTs, with consistent reporting of sleep-related outcomes, are needed.